Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.
Tarhini AA, Rafique I, Floros T, Tran P, Gooding WE, Villaruz LC, Burns TF, Friedland DM, Petro DP, Farooqui M, Gomez-Garcia J, Gaither-Davis A, Dacic S, Argiris A, Socinski MA, Stabile LP, Siegfried JM.
Tarhini AA, et al. Among authors: farooqui m.
Cancer. 2017 Aug 1;123(15):2936-2944. doi: 10.1002/cncr.30717. Epub 2017 May 4.
Cancer. 2017.
PMID: 28472537
Free PMC article.
Clinical Trial.